Pluristem Therapeutics (PSTI) Getting Somewhat Positive Media Coverage, Study Finds

Media coverage about Pluristem Therapeutics (NASDAQ:PSTI) has been trending somewhat positive recently, Accern Sentiment reports. The research firm rates the sentiment of media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Pluristem Therapeutics earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 44.6377550126265 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.

Several research analysts have commented on PSTI shares. Zacks Investment Research downgraded Pluristem Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, July 4th. HC Wainwright set a $4.00 price objective on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 1st. Maxim Group set a $3.00 price objective on Pluristem Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 10th. ValuEngine raised Pluristem Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Finally, MED reissued a “positive” rating on shares of Pluristem Therapeutics in a research note on Monday, April 23rd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $3.60.

Shares of Pluristem Therapeutics remained flat at $$1.26 during midday trading on Friday, Marketbeat Ratings reports. The stock had a trading volume of 144,089 shares, compared to its average volume of 172,767. The firm has a market cap of $138.59 million, a P/E ratio of -3.92 and a beta of 0.32. Pluristem Therapeutics has a 12 month low of $1.09 and a 12 month high of $2.12.

Pluristem Therapeutics (NASDAQ:PSTI) last announced its quarterly earnings data on Thursday, May 10th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.08. equities analysts predict that Pluristem Therapeutics will post -0.24 EPS for the current fiscal year.

Pluristem Therapeutics Company Profile

Pluristem Therapeutics Inc, together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders.

See Also: Diversification

Insider Buying and Selling by Quarter for Pluristem Therapeutics (NASDAQ:PSTI)

Receive News & Ratings for Pluristem Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluristem Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply